187 completed, 47 recruiting, 36 terminated, 22 active not recruiting. 170 Phase 2, 109 Phase 1, 33 Not applicable, 24 Phase 3, 4 Early Phase 1.
Follow Histiocytic Disorders, Malignant: new trials by email Literature Review of Histiocytic Disorders, Malignant trials Research Report on Histiocytic Disorders, Malignant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults CARCIK CD123/33 infusion - AML (Acute Myeloid Leukemia), BPDCN | Phase 1 / Phase 2 | Recruiting | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | 18 | 2026-10-01 | 2026-10-16 |
| CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) Rapcabtagene autoleucel (YTB323) - Large-cell Lymphoma | Phase 1 | Not yet recruiting | Stanford University | 20 | 2026-09-01 | 2026-08-27 |
| Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics Glofitamab - Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | Joshua Brody | 16 | 2026-09-01 | 2026-08-05 |
| Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement pirtobrutinib+MTX+immunolchemotherapy - Pirtobrutinib, Immunochemotherapy | Phase 2 | Not yet recruiting | Pengpeng Xu | 24 | 2026-09-01 | 2026-09-11 |
| Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma Pirtobrutinib, Sotoclax+/- Obinutuzumab (PSO) Combination for B cell lymphoma - DLBCL - Diffuse Large B Cell Lymphoma, Richter Transformation | Phase 2 | Not yet recruiting | Changzhou No.2 People's Hospital | 40 | 2026-08-30 | 2026-08-06 |
| Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL Orelabrutinib Combined with Pola-R-CHP Regimen - DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk | Not applicable | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2026-08-30 | 2026-08-21 |
| Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL Pirtobrutinib+Pola-R-CHP - DLBCL - Diffuse Large B Cell Lymphoma, Pirtobrutinib | Phase 2 | Not yet recruiting | Changzhou No.2 People's Hospital | 48 | 2026-07-31 | 2026-08-06 |
| Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL Pirtobrutinib plus R-CHOP - DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy | Phase 2 | Not yet recruiting | Changzhou No.2 People's Hospital | 34 | 2026-07-30 | 2026-08-06 |
| Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab - DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma) | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 53 | 2026-07-25 | 2026-08-06 |
| Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma R-CHOP+Orelabrutinib, POLA-R-CHP+orelabrutinib, R-miniCHOP +orelabrutinib - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Ou Bai, MD/PHD | 66 | 2026-06-16 | 2026-07-01 |
| A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma SCTB35 injection, Rituxumab, Gemcitabine - DLBCL - Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | Sinocelltech Ltd. | 101 | 2026-06-04 | 2026-08-13 |
| Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP CL-Pola-R-CHP - DHL, THL | Phase 2 | Not yet recruiting | Ruijin Hospital | 28 | 2026-05-01 | 2026-04-27 |
| A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma CT1182 injection - B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 24 | 2026-04-30 | 2026-04-23 |
| Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma MDX2003 - Lymphoma, Waldenström Macroglobulinemia (WM) | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 180 | 2026-04-13 | 2026-05-04 |
| A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping C-Pola-R-CHP+X, CR-CHOP - DLBCL - Diffuse Large B Cell Lymphoma, Double Expressor Lymphoma | Phase 3 | Not yet recruiting | Ruijin Hospital | 156 | 2026-03-31 | 2026-04-06 |
| Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma. Cisplatin (modified schedule), Cisplatin, Dexametasone - DLBCL - Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | King Edward Medical University | 74 | 2026-03-18 | 2026-08-10 |
| Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma DLBCL - Diffuse Large B Cell Lymphoma | Not yet recruiting | Henan Cancer Hospital | 20 | 2026-03-10 | 2026-03-16 | |
| Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 96 | 2026-03-02 | 2026-04-13 |
| Glofitamab Combined With CAR-T Therapy in R/R DLBCL Glofitamab, Obinutuzumab, Axicabtagene Ciloleucel - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 24 | 2026-03-01 | 2026-01-08 |
Showing 20 of 346. Sign in to see all of them.
Dendritic Cell Sarcoma, Interdigitating (298) · Burkitt Lymphoma (200) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (189) · Lymphoma, Large B-Cell, Diffuse (169) · Lymphoma (157) · Recurrence (150) · Lymphoma, Follicular (148) · Lymphoma, Non-Hodgkin (142) · Leukemia, Lymphocytic, Chronic, B-Cell (139) · Lymphoma, Mantle-Cell (139) · Lymphoma, B-Cell, Marginal Zone (132) · Leukemia (125) · Leukemia, Myeloid, Acute (125) · Lymphoma, Large-Cell, Immunoblastic (122) · Hodgkin Disease (117)
Hemic and Lymphatic Diseases (346) · Neoplasms by Histologic Type (344) · Lymphatic Diseases (326) · Neoplasms (321) · Histiocytosis (303) · Immune System Diseases (283) · Immunoproliferative Disorders (283) · Lymphoproliferative Disorders (276) · Hematologic Diseases (238) · Lymphoma, B-Cell (229) · Pathological Conditions, Signs and Symptoms (212) · Pathologic Processes (211) · Disease Attributes (209) · Leukemia, Lymphoid (208)
Cyclophosphamide (87) · fludarabine phosphate (48) · Filgrastim (38) · Peripheral Blood Stem Cell Transplantation (36) · Cyclosporine (34) · Busulfan (33) · Mycophenolic Acid (33) · Radiotherapy (33) · Etoposide (30) · Methotrexate (30) · Whole-Body Irradiation (30) · Antilymphocyte Serum (28) · Rituximab (26) · Cytarabine (21) · Melphalan (21)
Fred Hutchinson Cancer Center (40) · National Cancer Institute (NCI) (23) · Children's Oncology Group (13) · Masonic Cancer Center, University of Minnesota (13) · Memorial Sloan Kettering Cancer Center (11) · Case Comprehensive Cancer Center (10) · Roswell Park Cancer Institute (10) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (8) · City of Hope Medical Center (7) · M.D. Anderson Cancer Center (6) · Dana-Farber Cancer Institute (5) · Northwestern University (5) · Mayo Clinic (4) · Ruijin Hospital (4) · The First Affiliated Hospital of Xiamen University (4)
United States (254) · China (28) · Canada (23) · Italy (18) · Australia (13) · France (13) · Germany (12) · Switzerland (12) · United Kingdom (10) · Puerto Rico (7) · Netherlands (6) · South Korea (6) · Austria (4) · Greece (4) · Israel (4)
Philip L. McCarthy, MD (5) · Brenda Sandmaier (4) · David Maloney (4) · Kenneth G. Lucas, MD (4) · Claudio G. Brunstein, MD, PhD (3) · David G. Savage, MD (3) · Ephraim J. Fuchs, MD (3) · Tanya Trippett, MD (3) · Thomas J. Walsh, MD (3) · Alan S. Wayne, MD (2) · Ann E. Woolfrey, MD (2) · Asad Bashey, MD, PhD (2) · Barbara Jean Bambach, MD (2) · Barry R. Meisenberg, MD (2)
PMID 32499241, PMID 33795208, PMID 34398557, PMID 34515338, PMID 34687939, PMID 37486616, PMID 10632319, PMID 10673703, PMID 10820362, PMID 12171484, PMID 15107815, PMID 15466923, PMID 15659500, PMID 16533779, PMID 16864853, PMID 17119113, PMID 17132719, PMID 17138821, PMID 17439836, PMID 17515574, PMID 17610262, PMID 17889355, PMID 17910637, PMID 17959855, PMID 18079362, PMID 18166803, PMID 18371107, PMID 18413641, PMID 18493992, PMID 18698002, PMID 18759768, PMID 18769450, PMID 18985718, PMID 18989154, PMID 18997171, PMID 19020548, PMID 19139736, PMID 19179301, PMID 19286996, PMID 19706886, PMID 19789316, PMID 19895612, PMID 19900571, PMID 1994541, PMID 20124511, PMID 20637881, PMID 20668228, PMID 20674758, PMID 21173095, PMID 21403127
P30CA015704 (13), U01CA097452 (9), P01CA018029 (7), P30CA006973 (7), P30CA043703 (7), P01CA015396 (5), P30CA033572 (5), P01CA078902 (4), P30CA008748 (4), P30CA016672 (4), U10CA098543 (4), P30CA015083 (3), P30CA068485 (3), P30CA072720 (3), U10CA081920 (3)